Sabra Healthcare REIT, Inc.
SBRA
$19.54
+1.19%
Sabra Healthcare REIT, Inc. is a real estate investment trust that owns and invests in healthcare real estate, primarily nursing facilities, assisted living centers, and mental health facilities, operating exclusively in the United States. The company is a specialized player in the healthcare REIT sector, focusing on the essential but often challenging skilled nursing and senior housing property segments. The current investor narrative revolves around the company's ability to navigate post-pandemic operational pressures in its tenant base, stabilize its portfolio occupancy and rent collections, and manage its balance sheet amidst a higher interest rate environment, with recent attention likely on quarterly earnings that show a trajectory of recovery in its core financial metrics.…
SBRA
Sabra Healthcare REIT, Inc.
$19.54
Investment Opinion: Should I buy SBRA Today?
Rating: Hold. The stock presents a conflicted profile of improving top-line fundamentals but deteriorating price action and volatile earnings, making a clear Buy or Sell signal premature.
The Hold thesis is supported by four key data points: 1) Revenue is recovering, up 16.2% YoY in Q4, 2) The company generates substantial FCF ($348.6M TTM) to support its 6.33% dividend yield, 3) Balance sheet leverage is moderate at a D/E of 0.90, and 4) The stock trades at a 13% discount on forward earnings (P/E of 25.68x vs. trailing 29.59x), implying some expectation of improvement. However, this is counterbalanced by a high absolute P/E and severe recent underperformance.
Key risks that could invalidate this neutral stance are a break below the $17.17 support level, a further decline in quarterly net income, or a compression in gross margin below 60%. This Hold would upgrade to a Buy if the forward P/E compresses below 20x while revenue growth is sustained above 10%, or if the stock establishes a clear technical base above $20. It would downgrade to a Sell if QoQ revenue growth turns negative or if the dividend payout ratio remains unsustainably above 1.5. Based on current metrics, the stock appears slightly overvalued relative to its own volatile earnings history, trading at a mid-range P/E of 29.59x versus its recent low of 16.74x.
Sign up to view all
SBRA 12-Month Price Forecast
The evidence is mixed, warranting a neutral stance. The fundamental picture shows green shoots with revenue growth, but these are overshadowed by poor price momentum and earnings instability. The high dividend yield provides a floor, but the elevated P/E requires flawless execution to justify. Confidence is medium because the direction of the next earnings report is critical. The stance would upgrade to bullish on confirmation of margin stabilization and a sustained break above $20.50. It would turn bearish on a break below $17.17 or a dividend coverage warning.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Sabra Healthcare REIT, Inc.'s 12-month outlook, with a consensus price target around $25.40 and implied upside of +30.0% versus the current price.
Average Target
$25.40
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$16 - $25
Analyst target range
Insufficient analyst coverage data is available to form a meaningful consensus, as the provided data indicates only one analyst providing revenue estimates, with no target price or recommendation distribution shown. This limited coverage is typical for smaller mid-cap REITs and can lead to higher volatility and less efficient price discovery, as institutional interest may be muted. The institutional ratings data shows recent actions from several firms, including Wells Fargo (Overweight), Citigroup (Buy), and UBS (Neutral), indicating a mixed but generally stable sentiment with no major downgrades in the past few months, though the absence of quantified targets limits the precision of any upside/downside calculation.
Bulls vs Bears: SBRA Investment Factors
The bear case currently holds stronger evidence, driven by severe technical breakdown, volatile and declining profitability, and a valuation that appears rich given the operational challenges. The bull case rests on a recovering revenue trajectory, robust free cash flow, and a defensive business model, but these positives are being overshadowed by recent price action and earnings volatility. The single most important tension in the investment debate is whether the company's 16.2% YoY revenue growth in Q4 2025 marks the beginning of a sustainable operational recovery that can stabilize margins and justify its elevated P/E of 29.59x, or if the recent -7.87% monthly price decline is a leading indicator of further fundamental deterioration and multiple compression.
Bullish
- Strong Revenue Growth Trajectory: Q4 2025 revenue of $211.9 million represents a 16.2% year-over-year increase, and the sequential growth from Q1's $183.5 million shows a clear recovery trend. This is critical for a REIT dependent on tenant rent collection and suggests improving operational fundamentals in its healthcare portfolio.
- Robust Free Cash Flow Generation: The company generated $348.6 million in trailing twelve-month free cash flow, providing significant capacity to fund its dividend and strategic investments. Strong FCF, coupled with a stable dividend yield of 6.33%, supports a shareholder return profile attractive to income investors.
- Solid Balance Sheet Leverage: A debt-to-equity ratio of 0.90 indicates a moderately leveraged balance sheet, which is manageable for a REIT and provides financial flexibility. The company's ability to maintain profitability (Q4 net margin of 12.85%) while servicing this debt is a positive sign of operational stability.
- Defensive Business Model & Low Beta: With a beta of 0.626, the stock has historically been about 37% less volatile than the broader market, offering defensive characteristics. This aligns with its focus on essential healthcare real estate, which provides recession-resilient cash flows.
Bearish
- Severe Recent Price Underperformance: The stock has declined -7.87% over the past month and is down -2.75% over three months, starkly underperforming the SPY by -6.21% and -16.41% respectively. Trading near $19.09, it sits at just 46% of its 52-week range, indicating persistent selling pressure and a breakdown in its trend.
- Volatile and Declining Profitability: Net income fell from $65.5 million in Q2 2025 to $27.2 million in Q4 2025, with the net margin compressing from 34.65% to 12.85% over the same period. This volatility in earnings, coupled with a gross margin decline from 67.35% to 62.05% from Q1 to Q4, signals significant operational pressure.
- Elevated Valuation Multiples: The stock trades at a trailing P/E of 29.59x and a forward P/E of 25.68x, which is high for a REIT, especially one with volatile earnings. The EV/EBITDA of 15.43x and P/S of 5.90x also suggest the market is pricing in a recovery that may not materialize quickly enough.
- Weak Liquidity Position: A current ratio of 0.56 indicates limited short-term liquidity, which could pose a risk in a higher interest rate environment if refinancing needs arise. While typical for REITs, this low ratio underscores dependence on stable operating cash flow and external capital markets.
SBRA Technical Analysis
The stock is in a clear downtrend over the short to medium term, with a 1-year price change of only +3.02% significantly underperforming the SPY's +20.84%, and a more pronounced -7.87% decline over the past month. Currently trading at $19.09, the price sits at approximately 46% of its 52-week range ($17.17 to $21.28), indicating it is much closer to its yearly lows than highs, which suggests potential oversold conditions or fundamental concerns outweighing any value opportunity. Recent momentum is decisively negative, with the stock down -2.75% over the past three months and -7.87% over the past month, a sharp acceleration of selling pressure that diverges from its modestly positive longer-term trend and signals a breakdown. The stock's beta of 0.626 indicates it has been about 37% less volatile than the market, but this defensive characteristic has not prevented significant recent underperformance, as evidenced by its -6.21 relative strength over one month. Key technical support is clearly defined at the 52-week low of $17.17, while resistance sits at the 52-week high of $21.28; a sustained break below $17.17 would likely trigger further technical selling, while a recovery above the $20 level is needed to suggest the downtrend is abating, though the low beta suggests moves may be muted relative to broader market swings.
Beta
0.63
0.63x market volatility
Max Drawdown
-16.6%
Largest decline past year
52-Week Range
$17-$21
Price range past year
Annual Return
+5.7%
Cumulative gain past year
| Period | SBRA Return | S&P 500 |
|---|---|---|
| 1m | -4.4% | -3.6% |
| 3m | -0.4% | +15.3% |
| 6m | +4.0% | +6.1% |
| 1y | +5.7% | +18.6% |
| ytd | +2.0% | +6.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SBRA Fundamental Analysis
Revenue growth has been positive but volatile on a quarterly basis, with Q4 2025 revenue of $211.9 million representing a solid 16.21% year-over-year increase, though this follows a more modest 4.2% sequential growth from Q3's $190.0 million. The quarterly trend shows revenue climbing from $183.5 million in Q1 2025 to the latest $211.9 million, indicating a recovering trajectory, which is critical for a REIT dependent on tenant rent payments. The company is profitable, with Q4 2025 net income of $27.2 million and a net margin of 12.85%, but profitability has fluctuated significantly, as seen in the higher Q2 2025 net income of $65.5 million (34.65% margin). Gross margin for Q4 2025 was 62.05%, which is consistent with its business model but down from the 67.35% seen in Q1 2025, suggesting some potential pressure on rental income or operating costs. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.90, and the company generates substantial operating cash flow, with Q4 2025 operating cash flow of $87.4 million and trailing twelve-month free cash flow of $348.6 million. However, the current ratio of 0.56 indicates limited short-term liquidity, which is typical for REITs that hold assets, not cash, but the robust FCF provides internal funding capacity for dividends and potential investments.
Quarterly Revenue
$211902000.0B
2025-12
Revenue YoY Growth
+0.16%
YoY Comparison
Gross Margin
+0.62%
Latest Quarter
Free Cash Flow
$348613000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SBRA Overvalued?
Given a positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 29.59x, while the forward P/E is 25.68x, indicating the market expects modest earnings growth, with the forward multiple implying a 13% discount to the trailing figure. Compared to sector averages, data is not available in the provided inputs for a direct industry P/E comparison, but the stock's own metrics show a Price/Sales ratio of 5.90x and an EV/EBITDA of 15.43x, which must be evaluated against healthcare REIT peers for context. Historically, the stock's own P/E ratio has varied widely; the most recent quarterly data shows a P/E of 43.37 as of Q4 2025, compared to a low of 16.74 in Q2 2025, indicating the current trailing P/E of 29.59x is below its recent peak but above the low, suggesting a mid-range valuation that may not be excessively demanding if earnings stabilize.
PE
29.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -70x~80x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on earnings volatility and margin pressure. Net income dropped 58% from Q2 to Q4 2025, and gross margin fell over 500 basis points in the same period, indicating potential issues with tenant health or rising property costs. The company's low current ratio of 0.56 highlights liquidity constraints, though this is partially offset by strong annual FCF of $348.6 million. The high payout ratio of 1.86 suggests the dividend is not fully covered by earnings, relying on other cash sources, which is unsustainable long-term.
Market & Competitive Risks are pronounced given the stock's valuation. Trading at a forward P/E of 25.68x and EV/EBITDA of 15.43x, SBRA carries a significant valuation compression risk if earnings growth disappoints or interest rates remain elevated, pressuring REIT multiples. The stock's low beta of 0.626 has not protected it from a -7.87% monthly decline, indicating company-specific issues outweigh defensive characteristics. A short ratio of 12.6 days reflects substantial market skepticism about the near-term outlook, which can fuel further downside momentum on any negative news.
The Worst-Case Scenario involves a continuation of operational pressures leading to a dividend cut, triggering a re-rating to a distressed valuation. If revenue growth stalls and margins compress further, the stock could test its 52-week low of $17.17. A realistic downside from the current price of $19.09 is approximately -10% to this technical support level. In a more severe scenario where FCF weakens and leverage becomes a concern, the stock could breach this low, potentially leading to a -15% to -20% decline, mirroring its recent max drawdown of -16.65%.
FAQ
The key risks are, in order of severity: 1) Operational Risk: Volatile and declining profitability, with net margin falling from 34.65% to 12.85% in the last two reported quarters. 2) Valuation Risk: High P/E (29.59x) and EV/EBITDA (15.43x) leave the stock vulnerable to multiple compression if growth stalls. 3) Liquidity & Dividend Risk: A low current ratio (0.56) and a payout ratio above 1.8 indicate the dividend relies on non-earnings cash flow, which may not be sustainable. 4) Sentiment Risk: High short interest (12.6 days to cover) and severe recent underperformance (-7.87% in one month) can create a negative feedback loop.
The 12-month outlook presents three scenarios. The Base Case (60% probability) sees the stock trading between $18.50 and $20.50, as slow, choppy recovery continues. The Bull Case (25% probability) projects a move to $21.28-$23.00 on accelerated operational improvement and a favorable rate environment. The Bear Case (15% probability) warns of a drop to $16.50-$17.17 if fundamentals worsen. The base case is most likely, assuming the company muddles through with modest growth but fails to decisively improve margins or investor sentiment in the near term.
SBRA appears slightly overvalued based on its current earnings profile. The trailing P/E of 29.59x and forward P/E of 25.68x are high for a REIT, especially one with net income that fell 58% from Q2 to Q4 2025. The EV/EBITDA of 15.43x also suggests a premium. The market is pricing in a significant earnings recovery that has yet to materialize consistently. While the stock is near its 52-week low, the valuation multiple is not distressed, indicating the price decline is more about deteriorating fundamentals than multiple compression alone.
SBRA is a speculative buy only for investors comfortable with high volatility and seeking high yield. The 6.33% dividend is attractive, but it is not fully covered by earnings (payout ratio 1.86). The stock has significant downside risk, trading near its 52-week low after a -7.87% monthly decline. A purchase here is a bet that the company's 16.2% YoY revenue growth in Q4 2025 marks a sustainable recovery. For most investors, a 'Hold' and wait-for-clarity approach is prudent until earnings volatility subsides.
SBRA is unsuitable for short-term trading due to its low beta (0.626) and recent bearish trend, which offer poor momentum characteristics. It is primarily a long-term, income-oriented holding for investors willing to wait 2-3 years for a potential operational turnaround while collecting the dividend. The high yield provides a return cushion, but the volatility in earnings and price requires a long horizon to ride out uncertainty. A minimum holding period of 18-24 months is suggested to assess whether the revenue recovery is sustainable and margins can stabilize.